Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759857 | 0.83 | USP2 (0.62) | MAPK1ALDH1A1SMN1; SMN2KMT2ATSHR | |
| SCHEMBL4757991 | 0.83 | CA12 (0.65) | LMNAHTTALDH1A1PKMMEN1 | |
| SCHEMBL4075458 | 0.83 | ALDH1A1 (0.58) | LMNAMAPK1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13901771 | 0.80 | CYP3A4 (0.42) | LMNAALDH1A1PKMSMN1; SMN2MEN1 | |
| SCHEMBL635208 | 0.78 | ALDH1A1 (0.70) | LMNAHTTMAPK1ALDH1A1PKM | |
| SCHEMBL15077864 | 0.77 | LMNA (0.55) | LMNAHTTMAPK1ALDH1A1PKM | |
| SCHEMBL8355315 | 0.76 | ALDH1A1 (0.72) | LMNAHTTMAPK1ALDH1A1PKM | |
| SCHEMBL9293542 | 0.76 | LMNA (0.60) | LMNAHTTMAPK1ALDH1A1PKM | |
| SCHEMBL21820680 | 0.76 | ALDH1A1 (0.72) | LMNAHTTMAPK1ALDH1A1PKM | |
| SCHEMBL7130425 | 0.76 | ALDH1A1 (0.60) | LMNAHTTMAPK1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1668020-A2 | NOVEL ADENOSINE A SB 3 /SB RECEPTOR AGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005028489-A2 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | LMNA 3472/4885HTT 4129/4885MAPK1 2121/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | LMNA 4090/4885HTT 3986/4885MAPK1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.